These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34680805)

  • 1. Combined Resistance to Ceftolozane-Tazobactam and Ceftazidime-Avibactam in Extensively Drug-Resistant (XDR) and Multidrug-Resistant (MDR)
    Meschiari M; Orlando G; Kaleci S; Bianco V; Sarti M; Venturelli C; Mussini C
    Antibiotics (Basel); 2021 Oct; 10(10):. PubMed ID: 34680805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extensively drug-resistant
    Mendes Pedro D; Paulo SE; Santos CM; Fonseca AB; Melo Cristino J; Pereira ÁA; Caneiras C
    Front Microbiol; 2024; 15():1347521. PubMed ID: 38414772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature.
    Meschiari M; Franconi I; Bacca E; Bianco V; Orlando G; Cuomo G; Bedini A; Mussini C
    Infection; 2021 Jun; 49(3):549-553. PubMed ID: 33074365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated Genome-Wide Analysis of an Isogenic Pair of
    Huang W; Hamouche JE; Wang G; Smith M; Yin C; Dhand A; Dimitrova N; Fallon JT
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the
    Viala B; Zaidi FZ; Bastide M; Dumont Y; Le Moing V; Jean-Pierre H; Godreuil S
    Microb Drug Resist; 2019 Nov; 25(9):1325-1329. PubMed ID: 31225764
    [No Abstract]   [Full Text] [Related]  

  • 6. In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis.
    Nolan PJ; Jain R; Cohen L; Finklea JD; Smith TT
    Diagn Microbiol Infect Dis; 2021 Feb; 99(2):115204. PubMed ID: 33152675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.
    Sid Ahmed MA; Abdel Hadi H; Hassan AAI; Abu Jarir S; Al-Maslamani MA; Eltai NO; Dousa KM; Hujer AM; Sultan AA; Soderquist B; Bonomo RA; Ibrahim EB; Jass J; Omrani AS
    J Antimicrob Chemother; 2019 Dec; 74(12):3497-3504. PubMed ID: 31504587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant
    Contreras-Gómez MJ; Martinez JRW; Rivas L; Riquelme-Neira R; Ugalde JA; Wozniak A; García P; Munita JM; Olivares-Pacheco J; Alcalde-Rico M
    Front Pharmacol; 2022; 13():1007162. PubMed ID: 36263116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of
    Sid Ahmed MA; Khan FA; Hadi HA; Skariah S; Sultan AA; Salam A; Al Khal AL; Söderquist B; Ibrahim EB; Omrani AS; Jass J
    Antibiotics (Basel); 2022 Jan; 11(2):. PubMed ID: 35203733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftolozane-tazobactam and ceftazidime-avibactam activity against β-lactam-resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Enterobacterales clinical isolates from U.S. medical centres.
    Hirsch EB; Brigman HV; Zucchi PC; Chen A; Anderson JC; Eliopoulos GM; Cheung N; Gilbertsen A; Hunter RC; Emery CL; Bias TE
    J Glob Antimicrob Resist; 2020 Sep; 22():689-694. PubMed ID: 32353524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
    Humphries RM; Hindler JA; Wong-Beringer A; Miller SA
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections.
    Arca-Suárez J; Lasarte-Monterrubio C; Rodiño-Janeiro BK; Cabot G; Vázquez-Ucha JC; Rodríguez-Iglesias M; Galán-Sánchez F; Beceiro A; González-Bello C; Oliver A; Bou G
    J Antimicrob Chemother; 2021 Jan; 76(1):91-100. PubMed ID: 33083833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First Study of Antimicrobial Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Against
    Rahimzadeh M; Habibi M; Bouzari S; Asadi Karam MR
    Infect Drug Resist; 2020; 13():533-541. PubMed ID: 32110063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
    Alatoom A; Elsayed H; Lawlor K; AbdelWareth L; El-Lababidi R; Cardona L; Mooty M; Bonilla MF; Nusair A; Mirza I
    Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
    Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
    Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Dimer, but Not Monomer, of Tobramycin Potentiates Ceftolozane against Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa and Delays Resistance Development.
    Idowu T; Zhanel GG; Schweizer F
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 2.5-years within-patient evolution of a
    Boulant T; Jousset AB; Bonnin RA; Barrail-Tran A; Borgel A; Oueslati S; Naas T; Dortet L
    Antimicrob Agents Chemother; 2019 Sep; 63(12):. PubMed ID: 31636072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
    Zamudio R; Hijazi K; Joshi C; Aitken E; Oggioni MR; Gould IM
    Int J Antimicrob Agents; 2019 Jun; 53(6):774-780. PubMed ID: 30831233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbapenem-resistant Pseudomonas aeruginosa: an assessment of frequency of isolation from ICU versus non-ICU, phenotypic and genotypic profiles in a multinational population of hospitalized patients.
    Gill CM; Nicolau DP;
    Antimicrob Resist Infect Control; 2022 Nov; 11(1):146. PubMed ID: 36451179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by
    Daikos GL; da Cunha CA; Rossolini GM; Stone GG; Baillon-Plot N; Tawadrous M; Irani P
    Antibiotics (Basel); 2021 Sep; 10(9):. PubMed ID: 34572708
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.